AILT
MCID: ANG046
MIFTS: 51

Angioimmunoblastic T-Cell Lymphoma (AILT)

Categories: Blood diseases, Cancer diseases, Immune diseases, Rare diseases

Aliases & Classifications for Angioimmunoblastic T-Cell Lymphoma

MalaCards integrated aliases for Angioimmunoblastic T-Cell Lymphoma:

Name: Angioimmunoblastic T-Cell Lymphoma 12 20 58 54 15 17 32
Immunoblastic Lymphadenopathy 20 58 44 17
T-Cell Lymphoma, Aild Type 20 58
Lymphogranulomatosis X 20 58
Angioimmunoblastic Lymphadenopathy 71
Aitl 20
Ailt 58

Characteristics:

Orphanet epidemiological data:

58
angioimmunoblastic t-cell lymphoma
Age of onset: Adult;

Classifications:

Orphanet: 58  
Rare haematological diseases


External Ids:

Disease Ontology 12 DOID:0111147
MeSH 44 D007119
NCIt 50 C7528
SNOMED-CT 67 52097008
ICD10 32 C86.5
ICD10 via Orphanet 33 C86.5
UMLS via Orphanet 72 C0020981
Orphanet 58 ORPHA86886
UMLS 71 C0020981

Summaries for Angioimmunoblastic T-Cell Lymphoma

Disease Ontology : 12 A peripheral T-cell lymphoma characterized by autoimmune features and poor prognosis.

MalaCards based summary : Angioimmunoblastic T-Cell Lymphoma, also known as immunoblastic lymphadenopathy, is related to exanthem and lymphoma, hodgkin, classic, and has symptoms including exanthema An important gene associated with Angioimmunoblastic T-Cell Lymphoma is CXCL13 (C-X-C Motif Chemokine Ligand 13), and among its related pathways/superpathways are Innate Immune System and Class I MHC mediated antigen processing and presentation. The drugs Pirarubicin and Azacitidine have been mentioned in the context of this disorder. Affiliated tissues include lymph node, t cells and endothelial, and related phenotypes are hematopoietic system and cellular

Wikipedia : 74 Angioimmunoblastic T-cell lymphoma (AITL, sometimes misspelled AILT) (formerly known as... more...

Related Diseases for Angioimmunoblastic T-Cell Lymphoma

Diseases related to Angioimmunoblastic T-Cell Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 290)
# Related Disease Score Top Affiliating Genes
1 exanthem 31.5 SYK PDCD1 CD274
2 lymphoma, hodgkin, classic 31.3 TNFRSF8 TIA1 GZMB BCL6
3 lymphoma 31.3 TNFRSF8 TIA1 PDCD1 GZMB CXCL13 CD274
4 lymphoproliferative syndrome 31.2 TNFRSF8 TIA1 ITK BCL6
5 peripheral t-cell lymphoma 31.2 TNFRSF8 TIA1 TET2 SYK RHOA PDCD1
6 marginal zone b-cell lymphoma 31.1 TNFRSF8 MME BCL6
7 b-cell lymphoma 31.0 TNFRSF8 TIA1 SYK MME CXCL13 CD274
8 diffuse large b-cell lymphoma 31.0 TNFRSF8 SYK PDCD1 MME CD274 BCL6
9 anaplastic large cell lymphoma 31.0 TNFRSF8 TIA1 GZMB
10 nodular lymphocyte predominant hodgkin lymphoma 30.9 PDCD1 BCL6
11 t-cell lymphoma, subcutaneous panniculitis-like 30.8 TNFRSF8 TIA1 GZMB
12 lymphoma, non-hodgkin, familial 30.7 TNFRSF8 SYK RHOA MME GZMB CD28
13 hodgkin's lymphoma, lymphocytic-histiocytic predominance 30.6 TNFRSF8 BCL6
14 panniculitis 30.6 TNFRSF8 TIA1 GZMB
15 mycosis fungoides 30.6 TNFRSF8 TIA1 GZMB CD28
16 primary cutaneous t-cell lymphoma 30.6 TNFRSF8 PDCD1
17 allergic disease 30.5 TNFRSF8 SYK PDCD1 ICOS
18 lymphoblastic lymphoma 30.5 TNFRSF8 MME BCL6
19 hepatosplenic t-cell lymphoma 30.5 TIA1 GZMB
20 mantle cell lymphoma 30.5 SYK MME CD274 BCL6
21 lymphomatoid papulosis 30.4 TNFRSF8 TIA1 GZMB
22 composite lymphoma 30.4 TNFRSF8 TIA1 MME GZMB CD274 BCL6
23 thrombocytopenia 30.3 TNFRSF8 TBX21 SYK PDCD1 ITK GZMB
24 burkitt lymphoma 30.2 VAV1 TNFRSF8 MME CXCL13 BCL6
25 leukemia, chronic lymphocytic 30.1 TNFRSF8 SYK MME CD28 CD274 BCL6
26 mature t-cell and nk-cell lymphoma 30.1 TNFRSF8 TIA1 TET2 MME IDH2 GZMB
27 myeloma, multiple 30.1 TET2 MAF IDH2 CD28 CD274 BCL6
28 leukemia, acute myeloid 29.8 VAV1 TNFRSF8 TET2 SYK MME IDH2
29 systemic lupus erythematosus 29.4 TBX21 SYK PDCD1 ICOS CXCL13 CD28
30 splenomegaly 10.7
31 polyclonal hypergammaglobulinemia 10.6
32 hemolytic anemia 10.6
33 hypereosinophilic syndrome 10.5
34 anemia, autoimmune hemolytic 10.5
35 pure red-cell aplasia 10.5
36 purpura 10.5
37 vasculitis 10.5
38 red cell aplasia 10.5
39 follicular lymphoma 10.5
40 pancytopenia 10.5
41 bladder lymphoma 10.4 MME BCL6
42 ureteral lymphoma 10.4 MME BCL6
43 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 10.4
44 nephrotic syndrome 10.4
45 glomerulonephritis 10.4
46 plasma cell leukemia 10.4
47 angioimmunoblastic lymphadenopathy with dysproteinemia 10.4
48 chest wall lymphoma 10.4 MME BCL6
49 prostate lymphoma 10.4 MME BCL6
50 epiglottis neoplasm 10.4 MME BCL6

Graphical network of the top 20 diseases related to Angioimmunoblastic T-Cell Lymphoma:



Diseases related to Angioimmunoblastic T-Cell Lymphoma

Symptoms & Phenotypes for Angioimmunoblastic T-Cell Lymphoma

UMLS symptoms related to Angioimmunoblastic T-Cell Lymphoma:


exanthema

MGI Mouse Phenotypes related to Angioimmunoblastic T-Cell Lymphoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.3 BCL6 CD274 CD28 CXCL13 ICOS ITK
2 cellular MP:0005384 10.21 BCL6 CD274 CD28 CXCL13 ITK MME
3 immune system MP:0005387 10.21 BCL6 CD274 CD28 CXCL13 ICOS ITK
4 endocrine/exocrine gland MP:0005379 10.18 BCL6 CD28 ICOS ITK PDCD1 PDCD1LG2
5 homeostasis/metabolism MP:0005376 10.13 BCL6 CD274 CD28 ICOS MAF MME
6 liver/biliary system MP:0005370 9.7 BCL6 MAF MME PDCD1 RC3H1 SYK
7 neoplasm MP:0002006 9.56 CD28 ICOS IDH2 PDCD1 PDCD1LG2 RC3H1
8 no phenotypic analysis MP:0003012 9.17 BCL6 CD274 ICOS PDCD1LG2 RC3H1 SYK

Drugs & Therapeutics for Angioimmunoblastic T-Cell Lymphoma

Drugs for Angioimmunoblastic T-Cell Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 149)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pirarubicin Investigational Phase 4 72496-41-4
2
Azacitidine Approved, Investigational Phase 3 320-67-2 9444
3
Oxaliplatin Approved, Investigational Phase 2 61825-94-3 5310940 9887054 6857599 43805
4
Busulfan Approved, Investigational Phase 2 55-98-1 2478
5
Methotrexate Approved Phase 2 1959-05-2, 59-05-2 126941
6
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
7
alemtuzumab Approved, Investigational Phase 2 216503-57-0
8
Lenograstim Approved, Investigational Phase 2 135968-09-1
9
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
10
Carboplatin Approved Phase 2 41575-94-4 10339178 498142 38904
11
Melphalan Approved Phase 2 148-82-3 4053 460612
12
Mechlorethamine Approved, Investigational Phase 2 51-75-2 4033
13
Sargramostim Approved, Investigational Phase 2 123774-72-1, 83869-56-1
14
Everolimus Approved Phase 1, Phase 2 159351-69-6 6442177 70789204
15
Sirolimus Approved, Investigational Phase 1, Phase 2 53123-88-9 5284616 6436030
16
Deferasirox Approved, Investigational Phase 2 201530-41-8 5493381 214348
17
Iron Approved Phase 2 7439-89-6 23925 29936
18
Levoleucovorin Approved, Investigational Phase 1, Phase 2 68538-85-2 149436
19
Pembrolizumab Approved Phase 1, Phase 2 1374853-91-4
20
Vidarabine Approved, Investigational Phase 2 24356-66-9 32326 21704
21
Thiotepa Approved, Investigational Phase 2 52-24-4 5453
22
Daunorubicin Approved Phase 2 20830-81-3 30323
23
Gemcitabine Approved Phase 2 95058-81-4 60750
24
Romidepsin Approved, Investigational Phase 1, Phase 2 128517-07-7 5352062
25
Etoposide Approved Phase 2 33419-42-0 36462
26
Ifosfamide Approved Phase 2 3778-73-2 3690
27
Vincristine Approved, Investigational Phase 1, Phase 2 2068-78-2, 57-22-7 5978
28
Doxorubicin Approved, Investigational Phase 1, Phase 2 23214-92-8 31703
29
Prednisone Approved, Vet_approved Phase 2 53-03-2 5865
30 Prednisolone acetate Approved, Vet_approved Phase 2 52-21-1
31
Prednisolone Approved, Vet_approved Phase 2 50-24-8 5755
32
Methylprednisolone hemisuccinate Approved Phase 2 2921-57-5
33
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 6741
34
Prednisolone phosphate Approved, Vet_approved Phase 2 302-25-0
35
Panobinostat Approved, Investigational Phase 2 404950-80-7 6918837
36
Clofarabine Approved, Investigational Phase 1, Phase 2 123318-82-1 119182
37
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2 1177-87-3
38
Daratumumab Approved Phase 2 945721-28-8
39
Cisplatin Approved Phase 2 15663-27-1 84093 441203 2767
40
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 5743
41
Lenalidomide Approved Phase 2 191732-72-6 216326
42
rituximab Approved Phase 2 174722-31-7 10201696
43
Clotrimazole Approved, Vet_approved Phase 2 23593-75-1 2812
44
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
45
Venetoclax Approved, Investigational Phase 2 1257044-40-8 49846579
46
Ipilimumab Approved Phase 1, Phase 2 477202-00-9
47
nivolumab Approved Phase 2 946414-94-4
48
Phenylalanine Approved, Investigational, Nutraceutical Phase 2 63-91-2 6140
49
Folic acid Approved, Nutraceutical, Vet_approved Phase 1, Phase 2 59-30-3 6037
50
Valine Approved, Nutraceutical Phase 1, Phase 2 72-18-4 6287

Interventional clinical trials:

(show top 50) (show all 113)
# Name Status NCT ID Phase Drugs
1 An Open-label,Multicenter Randomised Study of CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for the New Diagnosed Young Patients With T Cell Non-hodgkin Lymphoma Unknown status NCT01746992 Phase 4 Cyclophosphamide 750mg/m2;Vincristine 1.4mg/m2;Doxorubicin 50mg/m2;prednisone 60mg/m2;ifosfamide 2000mg/m2;pirarubicin 50mg/m2;pirarubicin 25mg/m2;Etoposide phosphate 100mg/m2;methotrexate 1500mg/m2
2 Phase III Study of CHOP-14 Plus or Minus Alemtuzumab in Peripheral T-cell Lymphoma of the Elderly Unknown status NCT00725231 Phase 3 chemotherapy
3 Randomized Phase 3 Study Evaluating the Efficacy and the Safety of Oral Azacitidine (CC-486) Compared to Investigator's Choice Therapy in Patient With Relapsed or Refractory Angioimmunoblastic T Cell Lymphoma Recruiting NCT03593018 Phase 3 Oral azacitidine;Romidepsin;Bendamustine;Gemcitabine
4 Randomized Phase 3 Study Evaluation the Efficacy and Safety of Oral Azacitidine(CC-486) Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory Angioimmunoblastic T Cell Lymphoma Recruiting NCT03703375 Phase 3 Azacitidine;Romidepsin;Gemcitabine
5 Chidamide With PET Regimen for Angioimmunoblastic T Cell Lymphoma, a Multicentric, Single Arm, Open Label Phase II Clinical Trial Unknown status NCT03273452 Phase 2 Chidamide
6 Chimeric Antigen Receptor-Modified pNK Cells for CD7 Positive Relapsed or Refractory Leukemia and Lymphoma Unknown status NCT02742727 Phase 1, Phase 2
7 Phase II Trial of Fludarabine & Cyclophosphamide Followed by Thalidomide for Angioimmunoblastic Lymphoma Unknown status NCT00958854 Phase 2 cyclophosphamide;fludarabine phosphate;thalidomide
8 STUDY OF THE EFFICACY AND SAFETY OF FIRST LINE TREATMENT WITH CHOP AND LENALIDOMIDE (Rev-CHOP) IN PATIENTS AGED FROM 60 TO 80 YEARS WITH PREVIOUSLY UNTREATED ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA (AITL) Completed NCT01553786 Phase 2 Lenalidomide
9 A Phase II Study of Oxaliplatin in Relapsed and Refractory Non-Hodgkin's Lymphoma Completed NCT00006473 Phase 2 oxaliplatin
10 A Phase 1/2, Multicenter, Open-Label, Dose-Escalation Study of AG-221 in Subjects With Advanced Solid Tumors, Including Glioma, and With Angioimmunoblastic T-cell Lymphoma, That Harbor an IDH2 Mutation Completed NCT02273739 Phase 1, Phase 2 AG-221
11 Phase II Study of MK-2206 in Patients With Relapsed Lymphoma Completed NCT01258998 Phase 2 Akt inhibitor MK2206
12 A Phase II Study to Evaluate the Efficacy of Posttransplant Cyclophosphamide for Prevention of Chronic Graft-versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation Completed NCT01427881 Phase 2 cyclophosphamide;cyclosporine;fludarabine phosphate;busulfan
13 High-dose Busulfan, High-dose Cyclophosphamide, and Allogeneic Bone Marrow Transplantation for Leukemia, Myelodysplastic Syndromes, Multiple Myeloma and Lymphoma Completed NCT01177371 Phase 2 busulfan;cyclophosphamide;methylprednisolone;methotrexate;cyclosporine
14 A Multi-Center Study of Nonmyeloablative Conditioning With TBI or Fludarabine/TBI for HLA-matched Related Hematopoietic Cell Transplantation for Treatment of Hematologic Malignancies With Post Grafting Immunosuppression With Tacrolimus and Mycophenolate Mofetil Completed NCT00089011 Phase 2 fludarabine phosphate;mycophenolate mofetil;tacrolimus
15 Campath® [Alemtuzumab] Dose Escalation, Low-Dose TBI and Fludarabine Followed by HLA Class I Mismatched Donor Stem Cell Transplantation for Patients With Hematologic Malignancies - A Multi-Center Trial Completed NCT00040846 Phase 2 fludarabine phosphate;mycophenolate mofetil;cyclosporine
16 A Phase II Study of Sorafenib (BAY 43-9006) in Recurrent Aggressive Non-Hodgkin's Lymphoma Completed NCT00131937 Phase 2 sorafenib tosylate
17 A Phase II Study Evaluating the Efficacy of Gemcitabine, Carboplatin, and Dexamethasone and Rituximab for Previously Treated Lymphoid Malignancies Completed NCT00072514 Phase 2 gemcitabine hydrochloride;carboplatin;dexamethasone
18 Induction of Mixed Hematopoietic Chimerism in Patients Using Fludarabine, Low Dose TBI, PBSC Infusion and Post-Transplant Immunosuppression With Cyclosporine and Mycophenolate Mofetil Completed NCT00006251 Phase 1, Phase 2 fludarabine phosphate;cyclosporine;mycophenolate mofetil
19 Phase II Trial of the Aurora Kinase A Inhibitor MLN8237, in Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma Completed NCT01466881 Phase 2 Alisertib
20 Pilot Study of Prophylactic Dose-Escalation Donor Lymphocyte Infusion After T Cell Depleted Allogeneic Stem Cell Transplant in High Risk Patients With Hematologic Malignancies Completed NCT01839916 Phase 2
21 A Phase II Study of Cyclophosphamide, Etoposide, Vincristine and Prednisone (CEOP) Alternating With Pralatrexate (P) as Front Line Therapy for Patients With Stage II, III and IV Peripheral T-Cell Non-Hodgkin Lymphoma Completed NCT01336933 Phase 2 prednisone;cyclophosphamide;etoposide;Vincristine;pralatrexate
22 A Phase I/II Study of Vorinostat Plus Rituximab, Ifosphamide, Carboplatin, and Etoposide for Patients With Relapsed or Refractory Lymphoid Malignancies or Untreated T- or Mantle Cell Lymphoma Completed NCT00601718 Phase 1, Phase 2 vorinostat;ifosfamide;carboplatin;etoposide
23 A Phase II Study of Bendamustine (B), Etoposide (E), Dexamethasone (D), and GCSF for Peripheral Blood Hematopoietic Stem Cell Mobilization (BED) Completed NCT01110135 Phase 2 bendamustine hydrochloride;dexamethasone;etoposide
24 Study of the Efficacy and the Safety of First Line Treatment With CHOP Plus Rituximab (R-CHOP) in Patients Aged 60 to 80 Years With Previously Untreated T-cell Angioimmunoblastic Lymphoma (AIL). Completed NCT00169156 Phase 2 Rituximab;Prednisone;Doxorubicine;Cyclophosphamide;Vincristine
25 Campath (Alemtuzumab) Dose Escalation, Low-Dose TBI and Fludarabine Followed by HLA Class II Mismatched Donor Stem Cell Transplantation for Patients With Hematologic Malignancies: A Multicenter Trial Completed NCT00118352 Phase 2 fludarabine phosphate;cyclosporine;mycophenolate mofetil
26 Prolonged Mycophenolate Mofetil and Truncated Cyclosporine Postgrafting Immunosuppression to Reduce Life-Threatening GVHD After Unrelated Donor Peripheral Blood Cell Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancies and Renal Cell Carcinoma - A Multi-Center Trial Completed NCT00078858 Phase 1, Phase 2 fludarabine phosphate;cyclosporine;mycophenolate mofetil
27 Nonmyeloablative Hematopoietic Stem Cell Transplantation for Patients With High-Risk Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Phase II Trial of Combined Immunosuppression Before and After Transplantation Completed NCT00049504 Phase 2 cyclophosphamide;fludarabine phosphate;tacrolimus;mycophenolate mofetil
28 A Phase I/II Clinical Trial of the mTor Inhibitor RAD001 (Everolimus) in Combination With Lenalidomide (Revlimid) for Patients With Relapsed or Refractory Lymphoid Malignancy Completed NCT01075321 Phase 1, Phase 2 everolimus;lenalidomide
29 A Phase 1b/2a Study of ABT-888 in Combination With Bendamustine +/- Rituximab in Lymphoma, Multiple Myeloma and Solid Tumors Completed NCT01326702 Phase 1, Phase 2 Bendamustine Hydrochloride;Veliparib
30 Impact of Intervention With Deferasirox on the Immune Function of Patients With Hematologic Diseases and Transfusion-Related Iron Overload Completed NCT01273766 Phase 2 deferasirox
31 A Phase I/II Study of RAD001 Combined With CHOP in Newly Diagnosed Peripheral T-cell Lymphomas Completed NCT01198665 Phase 1, Phase 2 RAD001 (Everolimus)
32 A Phase II Study of 506U78 in Patients With Previously Systemically Untreated Cutaneous T-cell Lymphoma (CTCL) or With Refractory or Relapsed Non-cutaneous Peripheral T-cell Lymphoma (PTCL) Completed NCT00005080 Phase 2 nelarabine
33 A Phase II Trial of Reduced Intensity Allogeneic Stem Cell Transplantation With Fludarabine, Melphalan and Low Dose Total Body Irradiation Completed NCT01529827 Phase 2 fludarabine phosphate;melphalan;tacrolimus;mycophenolate mofetil;methotrexate
34 A Phase I/II Study of the Histone Deacetylase (HDAC) Inhibitor LBH589 (Panobinostat) in Combination With mTOR Inhibitor RAD001 (Everolimus) in Patients With Relapsed Multiple Myeloma or Lymphoma Completed NCT00918333 Phase 1, Phase 2 panobinostat;everolimus
35 An Open-label Phase 2 Study of Intravenous Bortezomib and Oral Panobinostat (LBH589) in Adult Patients With Relapsed/Refractory Peripheral T-cell Lymphoma or NK/T-cell Lymphoma After Failure of Conventional Chemotherapy Completed NCT00901147 Phase 2 panobinostat and bortezomib
36 A Phase 2, Open-Label Study to Evaluate the Safety and Efficacy of Chidamide Combined With CHOP(Cyclophosphamide, Doxorubicin, Vincristine, Prednisone ) in Untreated Subjects With Angioimmunoblastic T Cell Lymphoma Recruiting NCT03853044 Phase 2 Chidamide;Cyclophosphamide;Doxorubicin;Vincristine;Prednisone
37 A Single Arm, Open Label, Multi-centre, Phase I/II Study Evaluating the Safety and Clinical Activity of AUTO4, a CAR T-cell Treatment Targeting TRBC1, in Patients With Relapsed or Refractory TRBC1 Positive Selected T Cell Non-Hodgkin Lymphoma Recruiting NCT03590574 Phase 1, Phase 2
38 A Phase 1/2 Study of Pembrolizumab Plus Pralatrexate for Treatment of Relapsed or Refractory Peripheral T-Cell Lymphomas Recruiting NCT03598998 Phase 1, Phase 2 Pralatrexate
39 A Two Step Approach to Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Hematologic Malignancies Recruiting NCT01760655 Phase 2 Fludarabine phosphate;Thiotepa;Cyclophosphamide;Tacrolimus;Mycophenolate mofetil
40 A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL) Recruiting NCT02588651 Phase 2 Brentuximab vedotin
41 A Phase 2 Study of Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (CHEP-BV) Followed by BV Consolidation in Patients With CD30-Positive Peripheral T-Cell Lymphomas Recruiting NCT03113500 Phase 2 Brentuximab Vedotin;Cyclophosphamide;Doxorubicin;Doxorubicin Hydrochloride;Etoposide;Etoposide Phosphate;Prednisone
42 Phase II Study of Romidepsin Plus Lenalidomide for Patients With Previously Untreated PTCL Recruiting NCT02232516 Phase 2 romidepsin;lenalidomide
43 A Phase I/II Study of Pembrolizumab (MK-3475) in Combination With Romidepsin in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma Recruiting NCT03278782 Phase 1, Phase 2 Romidepsin
44 A Phase II Study of the Histone Deacetylase (HDAC) Inhibitor LBH589 (Panobinostat) in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma Active, not recruiting NCT01261247 Phase 2 panobinostat
45 A Phase 2, Open-Label Study of BGB-A317 in Patients With Relapsed or Refractory Mature T- and NK- Neoplasms Active, not recruiting NCT03493451 Phase 2 Tislelizumab
46 CEOP/IVE/GDP Compared With CEOP as the First-line Therapy for Newly Diagnosed Adult Patients With Peripheral T-cell Lymphoma (PTCL) Active, not recruiting NCT02533700 Phase 2 CEOP/IVE/GDP chemotherapy regimen;CEOP chemotherapy regimen for 6 cycles
47 A Phase I/II Trial of CHOEP Chemotherapy Plus Lenalidomide as Front Line Therapy for Patients With Stage II, III and IV Peripheral T-Cell Non-Hodgkin's Lymphoma Active, not recruiting NCT02561273 Phase 1, Phase 2 Cyclophosphamide;Doxorubicin Hydrochloride;Etoposide;Lenalidomide;Prednisone;Vincristine Sulfate
48 A Phase II Study of Oral Clofarabine in Patients With Relapsed/Refractory Non-Hodgkin Lymphoma Active, not recruiting NCT00644189 Phase 1, Phase 2 Clofarabine
49 CHEMO-T: Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (CHOP) Versus Gemcitabine, Cisplatin and Methyl Prednisolone (GEM-P) in the First Line Treatment Of T-cell Lymphoma,a Multicentre Randomised Phase II Study Active, not recruiting NCT01719835 Phase 2 Cyclophosphamide;Gemcitabine;Doxorubicin;Vincristine;Prednisolone;methylprednisolone;Cisplatin
50 Romidepsin in Combination With CHOEP as First Line Treatment Before Hematopoietic Stem Cell Transplantation in Young Patients With Nodal Peripheral T-cell Lymphomas: a Phase I-II Study Active, not recruiting NCT02223208 Phase 1, Phase 2 Ro-CHOEP-21 (PHASE I);Ro-CHOEP-21 (PHASE II)

Search NIH Clinical Center for Angioimmunoblastic T-Cell Lymphoma

Cochrane evidence based reviews: immunoblastic lymphadenopathy

Genetic Tests for Angioimmunoblastic T-Cell Lymphoma

Anatomical Context for Angioimmunoblastic T-Cell Lymphoma

MalaCards organs/tissues related to Angioimmunoblastic T-Cell Lymphoma:

40
Lymph Node, T Cells, Endothelial, Bone Marrow, Liver, B Cells, Skin

Publications for Angioimmunoblastic T-Cell Lymphoma

Articles related to Angioimmunoblastic T-Cell Lymphoma:

(show top 50) (show all 1217)
# Title Authors PMID Year
1
Identification of CXCL13 as a new marker for follicular dendritic cell sarcoma. 54 61
18792075 2008
2
Expression of CXCL13, a chemokine highly upregulated in germinal center T-helper cells, distinguishes angioimmunoblastic T-cell lymphoma from peripheral T-cell lymphoma, unspecified. 61 54
16680156 2006
3
Expression of CXCL13 by neoplastic cells in angioimmunoblastic T-cell lymphoma (AITL): a new diagnostic marker providing evidence that AITL derives from follicular helper T cells. 54 61
16625095 2006
4
CD10 and BCL6 expression in the diagnosis of angioimmunoblastic T-cell lymphoma: utility of detecting CD10+ T cells by flow cytometry. 61 54
16084948 2005
5
Molecular-cytogenetic characterization of non-Hodgkin's lymphoma with double and cryptic translocations of the immunoglobulin heavy chain gene. 61 54
15370207 2004
6
Acute Brain Stroke Evolution Detected by 18F-FDG PET/CT and MRI Justifies the Discordance of Lesions in a Patient With Lymphoproliferative Syndrome. 61
33443953 2021
7
Clinicopathologic Features of Peripheral T-Cell Lymphoma in Sub-Saharan Africa. 61
33527979 2021
8
Correlation of mutational landscape and survival outcome of peripheral T-cell lymphomas. 61
33546774 2021
9
Early detection of T-cell lymphoma with T follicular helper phenotype by RHOA mutation analysis. 61
33567811 2021
10
Comprehensive Epstein-Barr Virus Transcriptome by RNA-Sequencing in Angioimmunoblastic T Cell Lymphoma (AITL) and Other Lymphomas. 61
33557089 2021
11
Novel tumour-infiltrating lymphocyte-related risk stratification based by flow cytometry for patients with de novo angioimmunoblastic T cell lymphoma. 61
33389024 2021
12
Integrative analysis of a phase 2 trial combining lenalidomide with CHOP in angioimmunoblastic T-cell lymphoma. 61
33496747 2021
13
The mutation of BCOR is highly recurrent and oncogenic in mature T-cell lymphoma. 61
33468080 2021
14
Busulfan, etoposide, cytarabine, and melphalan as a high-dose regimen for autologous stem cell transplantation in peripheral T-cell lymphomas. 61
33205337 2021
15
Linking the KIR phenotype with STAT3 and TET2 mutations to identify chronic lymphoproliferative disorders of NK cells. 61
33512451 2021
16
Combination of brentuximab-vedotin and ifosfamide, carboplatin, etoposide in relapsed/refractory peripheral T-cell lymphoma. 61
33320379 2020
17
Angioimmunoblastic T-cell lymphoma after acute myeloid leukemia: Alleged common pathogenesis. A case report and literature review. 61
33363958 2020
18
Molecular Genetic Analysis With Flow Cytometry Sorting Identifies Angioimmunoblastic T-Cell Lymphoma and Concomitant De Novo Myelodysplastic Syndrome Arising From the Same Hematopoietic Progenitor. 61
33224395 2020
19
[The diagnostic value of flow cytometry in patients with lymphoma associated hemophagocytic syndrome]. 61
33256339 2020
20
[Angioimmunoblastic T-cell lymphoma with fever, arthritis and skin pigmentation: A case report]. 61
33331330 2020
21
Molecular epidemiology of IDH2 hotspot mutations in cancer and immunohistochemical detection of R172K, R172G, and R172M variants. 61
33017591 2020
22
Unique evolution of angioimmunoblastic T cell lymphoma to Epstein-Barr virus-positive plasma cell myeloma. 61
32514627 2020
23
Angioimmunoblastic T-cell lymphoma associated with immune checkpoint inhibitor treatment. 61
33294560 2020
24
Combination treatment of copanlisib and gemcitabine in relapsed/refractory PTCL (COSMOS): an open-label phase I/II trial. 61
33352201 2020
25
Successful Treatment of Primary Refractory Angioimmunoblastic T-cell Lymphoma With Cord Blood Transplantation. 61
32792303 2020
26
[Clinical characteristics and prognosis in 84 patients with angioimmunoblastic T-cell lymphoma: a single-center analysis]. 61
33333694 2020
27
Delayed diagnosis of Angioimmunoblast T-cell lymphoma presenting with type II Cryoglobulinemia and acute kidney injury: a case report and narrative review of the literature. 61
33160311 2020
28
Comparison of prognostic scores in transplant-ineligible patients with peripheral T-cell lymphoma not otherwise specified and angioimmunoblastic T-cell lymphoma: a retrospective study from the national hospital organization in Japan. 61
33167741 2020
29
Molecular insights into pathogenesis and targeted therapy of peripheral T cell lymphoma. 61
33292562 2020
30
[Pathological transformation of angioimmunoblastic T-cell lymphoma into diffuse large B-cell lymphoma: a case report]. 61
33333705 2020
31
T follicular helper phenotype predicts response to histone deacetylase inhibitors in relapsed/refractory peripheral T-cell lymphoma. 61
33002132 2020
32
Lymphomatoid papulosis mimicking relapsed angioimmunoblastic T-cell lymphoma on histology: the importance of clinicopathologic correlation. 61
33098681 2020
33
ICOS is widely expressed in cutaneous T-cell lymphoma, and its targeting promotes potent killing of malignant cells. 61
33095875 2020
34
Successful treatment with lenalidomide plus chidamide combination therapy in 3 heavily treated patients with non-Hodgkin lymphoma: Three cases report. 61
33120793 2020
35
Role of the IL-2 inducible tyrosine kinase ITK and its inhibitors in disease pathogenesis. 61
32808093 2020
36
Is triple-positive serology for Epstein-Barr virus (VCA-IgG, VCA-IgM, EBNA-IgG) a specific feature of angioimmunoblastic T-cell lymphoma? 61
31634059 2020
37
[Chylothorax due to angioimmunoblastic T-cell lymphoma: a case report]. 61
33190448 2020
38
Advances in understanding of angioimmunoblastic T-cell lymphoma. 61
32704161 2020
39
Combination of multicolor flow cytometry for circulating lymphoma cells and tests for the RHOAG17V and IDH2R172 hot-spot mutations in plasma cell-free DNA as liquid biopsy for the diagnosis of angioimmunoblastic T-cell lymphoma. 61
32476550 2020
40
Chemotherapy combined with radiotherapy for successful treatment of angioimmunoblastic T-cell lymphoma: a case report. 61
33046131 2020
41
A comprehensive analysis of RHOA mutation positive and negative angioimmunoblastic T-cell lymphomas by targeted deep sequencing, expression profiling and single cell digital image analysis. 61
32945366 2020
42
Pralatrexate and angioimmunoblastic T-cell lymphoma: time for a second look? 61
32729765 2020
43
RHOA mutation in follicular T-cell lymphoma: Clinicopathological analysis of 16 cases. 61
32648273 2020
44
Sequential Complications of Hypercalcemia, Necrotizing Granulomatous Vasculitis, and Aplastic Anemia Occurring in One Patient with Angioimmunoblastic T-cell Lymphoma. 61
33097193 2020
45
Efficacy and safety of single-agent pralatrexate for treatment of angioimmunoblastic T-cell lymphoma after failure of first line therapy: a pooled analysis. 61
32536233 2020
46
[Discordant lymphoma consisting of angioimmunoblastic T-cell lymphoma and diffuse large B-cell lymphoma: a case report]. 61
33113614 2020
47
Composite EBV-negative marginal zone lymphoma and angioimmunoblastic T-cell lymphoma presenting as multiple subcutaneous nodules. 61
32618566 2020
48
The efficacy and safety of Epstein-Barr virus-specific antigen peptide-activated cytotoxic T-cells treatment for refractory or recurrent angioimmunoblastic T-cell lymphoma: A prospective clinical observational study. 61
32083758 2020
49
A suggested immunohistochemical algorithm for the classification of T-cell lymphomas involving lymph nodes. 61
32479842 2020
50
Rare non-Hodgkin lymphoma of childhood and adolescence: A consensus diagnostic and therapeutic approach to pediatric-type follicular lymphoma, marginal zone lymphoma, and nonanaplastic peripheral T-cell lymphoma. 61
32452165 2020

Variations for Angioimmunoblastic T-Cell Lymphoma

Expression for Angioimmunoblastic T-Cell Lymphoma

Search GEO for disease gene expression data for Angioimmunoblastic T-Cell Lymphoma.

Pathways for Angioimmunoblastic T-Cell Lymphoma

Pathways related to Angioimmunoblastic T-Cell Lymphoma according to GeneCards Suite gene sharing:

(show all 21)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.85 VAV1 TNFRSF8 SYK RHOA PDCD1LG2 PDCD1
2
Show member pathways
13.28 VAV1 SYK PDCD1LG2 PDCD1 ITK ICOS
3
Show member pathways
13.26 VAV1 TNFRSF8 SYK RHOA ITK CXCL13
4
Show member pathways
12.77 VAV1 SYK RHOA ITK CD28
5
Show member pathways
12.47 VAV1 SYK ITK ICOS CD28
6
Show member pathways
12.34 VAV1 RHOA PDCD1 ITK ICOS CD28
7
Show member pathways
12.28 VAV1 SYK CD28 BCL6
8
Show member pathways
12.22 VAV1 SYK RHOA GZMB
9
Show member pathways
12.15 VAV1 SYK ITK ICOS CD28
10 11.89 PDCD1LG2 PDCD1 ICOS CD28 CD274
11 11.88 TNFRSF8 TBX21 SYK PDCD1LG2 PDCD1 ITK
12
Show member pathways
11.87 VAV1 PDCD1LG2 PDCD1 ICOS CD28 CD274
13
Show member pathways
11.79 VAV1 ITK CD28
14
Show member pathways
11.78 VAV1 SYK ITK
15
Show member pathways
11.74 PDCD1LG2 PDCD1 ITK CD274
16 11.6 TBX21 ICOS GZMB
17 11.32 PDCD1LG2 PDCD1 ICOS CXCL13 CD28 CD274
18 11.25 VAV1 RHOA ITK
19 11.1 PDCD1 ITK CD28
20 10.85 VAV1 SYK
21
Show member pathways
10.67 TET2 IDH2

GO Terms for Angioimmunoblastic T-Cell Lymphoma

Biological processes related to Angioimmunoblastic T-Cell Lymphoma according to GeneCards Suite gene sharing:

(show all 19)
# Name GO ID Score Top Affiliating Genes
1 immune system process GO:0002376 10.02 SYK PDCD1LG2 PDCD1 ITK CD274 BCL6
2 adaptive immune response GO:0002250 9.96 SYK PDCD1LG2 PDCD1 ITK CD274
3 cellular response to lipopolysaccharide GO:0071222 9.76 RHOA PDCD1LG2 CXCL13 CD274
4 neutrophil chemotaxis GO:0030593 9.75 VAV1 SYK CXCL13
5 cell surface receptor signaling pathway GO:0007166 9.72 SYK PDCD1LG2 CXCL13 CD28 CD274
6 positive regulation of T cell proliferation GO:0042102 9.65 PDCD1LG2 CD28 CD274
7 immune response GO:0006955 9.63 VAV1 PDCD1LG2 ICOS CXCL13 CD28 CD274
8 regulation of T cell proliferation GO:0042129 9.58 RC3H1 CD28
9 T cell activation GO:0042110 9.58 VAV1 ITK CD28
10 positive regulation of alpha-beta T cell differentiation GO:0046638 9.57 SYK RHOA
11 negative regulation of T-helper 17 cell differentiation GO:2000320 9.54 TBX21 RC3H1
12 positive regulation of interleukin-10 production GO:0032733 9.54 SYK CD28 CD274
13 positive regulation of isotype switching to IgG isotypes GO:0048304 9.52 TBX21 CD28
14 positive regulation of alpha-beta T cell proliferation GO:0046641 9.51 SYK CD28
15 germinal center formation GO:0002467 9.49 CXCL13 BCL6
16 regulation of germinal center formation GO:0002634 9.43 RC3H1 BCL6
17 beta selection GO:0043366 9.26 SYK RHOA
18 negative regulation of activated T cell proliferation GO:0046007 9.13 RC3H1 PDCD1LG2 CD274
19 T cell costimulation GO:0031295 9.1 VAV1 PDCD1LG2 PDCD1 ICOS CD28 CD274

Sources for Angioimmunoblastic T-Cell Lymphoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....